Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database

Aditya Joshi; Lauren Gawey; Carissa Saadi; Pragna Naidoo; Jonathan W Rick; Song Y Park; Anna L Cogen; Steven D Daveluy; Jennifer L Hsiao; Vivian Y Shi

doi:10.1016/j.jaad.2025.02.031

Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database

J Am Acad Dermatol. 2025 Feb 18:S0190-9622(25)00313-5. doi: 10.1016/j.jaad.2025.02.031. Online ahead of print.

Authors

Affiliations

¹ Department of Dermatology, University of Washington, Seattle, Washington; Creighton University School of Medicine, Phoenix, Arizona.
² Department of Dermatology, University of Washington, Seattle, Washington.
³ University of Arkansas School of Medicine, Little Rock, Arkansas.
⁴ Department of Dermatology, University of California Davis, Sacramento, California.
⁵ Department of Dermatology, Wayne State University, Detroit, Michigan.
⁶ Department of Dermatology, University of Southern California, Los Angeles, California.
⁷ Department of Dermatology, University of Washington, Seattle, Washington. Electronic address: vivian.shi.publications@gmail.com.

PMID: 39978679
DOI: 10.1016/j.jaad.2025.02.031

No abstract available

Keywords: FDA adverse event reporting system (FAERS); adalimumab; adverse events; biologics; hidradenitis suppurativa; infliximab; pharmacovigilance; postmarketing surveillance; safety profiling; secukinumab.